Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Recommendation of “Buy” from Analysts

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) has been assigned an average recommendation of “Buy” from the six analysts that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $56.50.

A number of analysts have issued reports on PHAT shares. The Goldman Sachs Group raised shares of Phathom Pharmaceuticals from a “sell” rating to a “neutral” rating and boosted their price objective for the company from $40.00 to $48.00 in a report on Wednesday, May 12th. Zacks Investment Research upgraded shares of Phathom Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 3rd.

In related news, Director David A. Socks sold 26,040 shares of the company’s stock in a transaction that occurred on Monday, June 28th. The shares were sold at an average price of $34.07, for a total transaction of $887,182.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Pharmaceutical Co Ltd Takeda sold 14,632 shares of the business’s stock in a transaction that occurred on Monday, May 3rd. The stock was sold at an average price of $38.28, for a total transaction of $560,112.96. Following the sale, the insider now directly owns 1,080,843 shares in the company, valued at $41,374,670.04. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 223,996 shares of company stock valued at $7,893,813. 39.80% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of PHAT. BlackRock Inc. grew its holdings in Phathom Pharmaceuticals by 10.3% during the 4th quarter. BlackRock Inc. now owns 790,880 shares of the company’s stock worth $26,273,000 after acquiring an additional 73,968 shares during the last quarter. Wells Fargo & Company MN grew its holdings in Phathom Pharmaceuticals by 30.9% during the 4th quarter. Wells Fargo & Company MN now owns 11,289 shares of the company’s stock worth $375,000 after acquiring an additional 2,662 shares during the last quarter. Rhumbline Advisers grew its holdings in Phathom Pharmaceuticals by 11.7% during the 4th quarter. Rhumbline Advisers now owns 12,200 shares of the company’s stock worth $405,000 after acquiring an additional 1,280 shares during the last quarter. Citigroup Inc. boosted its stake in shares of Phathom Pharmaceuticals by 194.6% in the 4th quarter. Citigroup Inc. now owns 3,294 shares of the company’s stock valued at $110,000 after purchasing an additional 2,176 shares during the last quarter. Finally, Trexquant Investment LP bought a new stake in shares of Phathom Pharmaceuticals in the 4th quarter valued at $208,000. 77.06% of the stock is currently owned by hedge funds and other institutional investors.

Shares of PHAT stock traded down $0.60 during midday trading on Friday, hitting $32.89. 464 shares of the company were exchanged, compared to its average volume of 119,984. The company has a debt-to-equity ratio of 0.22, a quick ratio of 5.94 and a current ratio of 5.94. The firm has a 50 day moving average price of $34.54. Phathom Pharmaceuticals has a 52 week low of $30.70 and a 52 week high of $50.78.

Phathom Pharmaceuticals (NASDAQ:PHAT) last announced its earnings results on Tuesday, May 11th. The company reported ($0.96) EPS for the quarter, topping the consensus estimate of ($1.11) by $0.15. Sell-side analysts forecast that Phathom Pharmaceuticals will post -3.65 EPS for the current year.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.

Featured Article: Treasury Bonds

Analyst Recommendations for Phathom Pharmaceuticals (NASDAQ:PHAT)

Receive News & Ratings for Phathom Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phathom Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.